Pseudoprogression or pseudoresponse: A challenge for the diagnostic imaging in Glioblastoma multiforme;Pseudoprogression oder Pseudorespons: Herausforderung an die Bildgebung des Glioblastoma multiforme

Wiener Medizinische Wochenschrift

Volumn 161, Issue 1-2, 2011, Pages 13-19

  Payer, Franz ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Glioblastoma; Macdonald criteria; Pseudoprogression; Pseudoresponse; Radionecrosis; RANO criteria

Indexed keywords

TEMOZOLOMIDE;

ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; DIAGNOSTIC IMAGING; GLIOBLASTOMA; HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PSEUDOPROGRESSION; PSEUDORESPONSE; RADIATION INDUCED NECROSIS; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; DACARBAZINE; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; DIFFUSION MAGNETIC RESONANCE IMAGING; DISEASE PROGRESSION; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; POSITRON-EMISSION TOMOGRAPHY; RADIATION INJURIES; SENSITIVITY AND SPECIFICITY; TUMOR BURDEN;

EID: 79952434335     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10354-010-0860-8     Document Type: Article

References (25)

1. Central Brain Tumor Registry of the United States: Statistical report: Primary brain tumors in the United States, 2000-2004. http://www.cbtrus.org/ reports/2007-2008/2007report.pdf
2. R Stupp WP Mason MJ van den Bent, et al. 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 987 996 1:CAS:528:DC%2BD2MXit1Wksbk%3D 10.1056/NEJMoa043330 15758009 (Pubitemid 40349501)
3. D Macdonald T Cascino SJ Schold, et al. 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1277 1280 1:STN:280:DyaK3c3ptlyitQ%3D%3D 2358840 (Pubitemid 20195640)
4. MJ van den Bent MA Vogelbaum PY Wen, et al. 2009 End point assessment in gliomas: Novel treatments limit usefulness of classical Macdonald's Criteria J Clin Oncol 27 2905 2908 10.1200/JCO.2009.22.4998 19451418
5. Macdonald DR. Neuro-oncology, SP-9, 2009
6. D Brandsma L Stalpers W Taal, et al. 2008 Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol 9 453 461 10.1016/S1470-2045(08)70125-6 18452856 (Pubitemid 351597795)
7. W Taal D Brandsma HG de Bruin, et al. 2008 Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide Cancer 113 405 410 1:CAS:528: DC%2BD1cXpt1Orsbs%3D 10.1002/cncr.23562 18484594
8. MC Chamberlain MJ Glantz L Chalmers, et al. 2007 Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma J Neurooncol 82 81 83 10.1007/s11060-006-9241-y 16944309
9. ER Gerstner MB McNamara AD Norden, et al. 2009 Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression J Neurooncol 94 97 101 1:CAS:528:DC%2BD1MXotFWhsLs%3D 10.1007/s11060-009-9809-4 19221865
10. AA Brandes E Franceschi A Tosoni, et al. 2008 MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients J Clin Oncol 26 2192 2197 10.1200/JCO.2007.14.8163 18445844
11. D Brandsma MJ van den Bent 2009 Pseudoprogression and pseudoresponse in the treatment of gliomas Curr Opin Neurol 22 633 638 10.1097/WCO. 0b013e328332363e 19770760
12. AJ Kumar NE Leeds GN Fuller, et al. 2000 Malignant gliomas: MR imaging spectrum of radiation therapy - and chemotherapy-induced necrosis oft he brain after treatment Radiology 217 377 384 1:STN:280:DC%2BD3crhtFeqsg%3D%3D 11058631
13. JD Ruben M Dally M Bailey, et al. 2006 Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy Int J Radiat Oncol Biol Phys 65 499 508 10.1016/j.ijrobp.2005.12. 002 16517093
14. JJ Vredenburgh A Desjardins JE Herndon, et al. 2007 Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma Clin Cancer Res 13 1253 1259 1:CAS:528:DC%2BD2sXhvF2htr8%3D 10.1158/1078-0432.CCR-06-2309 17317837 (Pubitemid 46424067)
15. HS Friedman MD Prados PY Wen, et al. 2009 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 28 4733 4740 1:CAS:528:DC%2BD1MXhtlGgtbbM 10.1200/JCO.2008.19.8721 19720927
16. Cloughesy T, Vredenburgh JJ, Day B, et al. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. ASCO, Abstract No: 2008, 2010
17. AD Norden GS Young K Setayesh, et al. 2008 Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 779 787 1:CAS:528:DC%2BD1cXitlyqs7o%3D 10.1212/01.wnl.0000304121.57857.38 18316689
18. RM Zuniga R Torcuator R Jain, et al. 2009 Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan J Neurooncol 91 329 336 1:CAS:528: DC%2BD1MXjvFemtQ%3D%3D 10.1007/s11060-008-9718-y 18953493
19. JJC Verhoeff O van Tellingen A Claes, et al. 2009 Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme BMC Cancer 16 444 10.1186/1471-2407-9-444
20. PY Wen DR Macdonald DA Reardon, et al. 2010 Updated response assessment criteria for high-grade gliomas: response assessment in Neuro-Oncology Working Group J Cin Oncol 28 1963 1972 10.1200/JCO.2009.26.3541
21. LS Hu LC Baxter KA Smith, et al. 2009 Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements Am J Neuroradiol 30 552 558 1:STN:280: DC%2BD1M3gtFSktg%3D%3D 10.3174/ajnr.A1377 19056837
22. RF Barajas JS Chang MR Segal, et al. 2009 Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibilityweighted contrast-enhanced perfusion MR imaging Radiology 253 486 496 10.1148/radiol.2532090007 19789240
23. R Mangla G Singh D Ziegelitz, et al. 2010 Changes in relative cerebral blood volume 1 month after radiation-Temozolomide therapy can help predict overall survival in patients with glioblastoma Radiology 256 575 584 10.1148/radiol.10091440 20529987
24. C Tsien CJ Galban TL Chenevert, et al. 2010 Parametric Response Map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma J Clin Oncol 28 2293 2299 1:CAS:528:DC%2BC3cXpsFSgt7c%3D 10.1200/JCO.2009.25.3971 20368564
25. ER Gerstner AG Sorensen RK Jain, et al. 2008 Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas Curr Opin Neurol 21 728 735 10.1097/WCO.0b013e328318402a 18989120